伊贝沙坦治疗慢性充血性心力衰竭的临床研究  

Clinical investigation of irbesartan in treatment of chronic congestive heart failure

作　　者：谭健强 

机构地区：[1]广东省开平市第一人民医院心内科,开平529300

出　　处：《中国临床药理学与治疗学》2002年第2期164-166,共3页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的 :评价伊贝沙坦 (irbesartan)治疗慢性充血性心力衰竭的疗效和安全性。方法 :80例慢性充血性心力衰竭患者随机分为常规治疗组 (对照组 )和伊贝沙坦组 (治疗组 ) ,各 4 0例 ,常规治疗组应用洋地黄、利尿剂、扩张血管药物常规治疗 ,伊贝沙坦组在常规治疗基础上口服伊贝沙坦 75～ 30 0mg·d- 1,12wk一疗程。结果 :与常规治疗组比较 ,临床症状和心功能明显改善 (P <0 .0 1) ,左室射血分数增加、左室重量减轻 (P <0 .0 5 ) ,不良反少且轻微。结论 :在常规治疗基础上 ,加用伊贝沙坦治疗慢性充血性心力衰竭疗效好且安全。AIM: To evaluate the therapeutic effect and safety of irbesartan in treatment of chronic congestive heart failure. METHODS: 80 patients with chronic congestive heart failure were randomizedly divided into the irbesartan group and the routine group, 40 cases in every group. The routine group was treated with nomal treatment digtoxin ethacrynicum and dilation vasocular, and the irbesartan group was treated with irbesartan 75- 300 mg one time daily based on the nomal treatment. The course of treatment was 12 weeks. RESULTS: Irbesartan could improve symptom and heart function clearly (P< 0.01), and inccrease left ventricular ejection faction(LVEF). The reverse left ventricular mass weigh decreased more significantly than routine group (P< 0.05). Little side effect was found. CONCLUSION: Irbesartan has better curative effect and safety in patients with chronic congestive heart failure.

关 键 词：伊贝沙坦 心力衰竭 左室射血分数 左室重量 

分 类 号：R969.4[医药卫生—药理学] R452[医药卫生—药学]